Ming De Yu
Presidente presso Chinese Pharmaceutical Enterprises Association
Profilo
Ming De Yu is currently the Chairman of the Chinese Pharmaceutical Enterprises Association and the Chairman of the China Medical Entrepreneur Association.
He previously served as the Honorary Chairman of Beijing Pharmaceutical Group Co., Ltd.
from 2004 to 2010.
He also held positions as an Independent Director at 3SBio, Inc., China Nuokang Bio-Pharmaceutical, Inc., and North China Pharmaceutical Co., Ltd.
Additionally, he served as a Director at Sichuan Kelun Pharmaceutical Co., Ltd.
and as an Independent Director at Shandong Wohua Pharmaceutical Co., Ltd.
from 2012 to 2016.
Mr. Yu started his career as the Chief Technology Officer & Head-Manufacturing at Liaoning Fuxin Pharmaceutical Co. and Fuxin Traditional Chinese Medicine Co. from 1978 to 1983.
He obtained his undergraduate degree from Dalian University of Technology.
Currently, Mr. Yu is still serving as the Chairman of the Chinese Pharmaceutical Enterprises Association and the Chairman of the China Medical Entrepreneur Association.
Posizioni attive di Ming De Yu
Società | Posizione | Inizio |
---|---|---|
Chinese Pharmaceutical Enterprises Association | Presidente | 01/01/2004 |
China Medical Entrepreneur Association | Presidente | - |
Precedenti posizioni note di Ming De Yu
Società | Posizione | Fine |
---|---|---|
SHANDONG WOHUA PHARMACEUTICAL CO., LTD. | Direttore/Membro del Consiglio | 06/01/2016 |
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Direttore/Membro del Consiglio | 01/01/2013 |
NORTH CHINA PHARMACEUTICAL COMPANY.LTD | Direttore/Membro del Consiglio | 01/01/2012 |
Fuxin Traditional Chinese Medicine Co. | Direttore Tecnico/Scientifico/R&S | 01/01/1983 |
Liaoning Fuxin Pharmaceutical Co. | Direttore Tecnico/Scientifico/R&S | 01/01/1983 |
Formazione di Ming De Yu
Dalian University of Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
3SBIO INC. | Health Technology |
NORTH CHINA PHARMACEUTICAL COMPANY.LTD | Health Technology |
SICHUAN KELUN PHARMACEUTICAL CO., LTD. | Health Technology |
SHANDONG WOHUA PHARMACEUTICAL CO., LTD. | Health Technology |
Aziende private | 6 |
---|---|
China Nuokang Bio-Pharmaceutical, Inc.
China Nuokang Bio-Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China. | Health Technology |
Beijing Pharmaceutical Group Co., Ltd.
Beijing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Pharmaceutical Group Co., Ltd. engages in the sale of Chinese medicines, chemical raw materials, chemical agents, antibiotics, biochemical drugs, and medical equipment. The company was found on March 28, 1987 and is headquartered in Beijing, China. | Health Technology |
Chinese Pharmaceutical Enterprises Association | |
China Medical Entrepreneur Association | |
Liaoning Fuxin Pharmaceutical Co. | |
Fuxin Traditional Chinese Medicine Co. |
- Borsa valori
- Insiders
- Ming De Yu